Baloxavirmarboxil

from Wikipedia, the free encyclopedia
Structural formula
Structural formula of Baloxavirmarboxil
General
Non-proprietary name Baloxavirmarboxil
other names
  • ({(12a R ) -12 - [(11 S ) -7,8-difluoro-6,11-dihydrodibenzo [ b , e ] thiepin-11-yl] -6,8-dioxo-3,4,6, 8,12,12a-hexahydro-1 H - [1,4] oxazino [3,4- c ] pyrido [2,1- f ] [1,2,4] triazin-7-yl} oxy) methylmethylcarbonat
  • S-033188
Molecular formula C 27 H 23 F 2 N 3 O 7 S
External identifiers / databases
CAS number 1985606-14-1
PubChem 124081896
Wikidata Q48333728
Drug information
Drug class

Antiviral

Mechanism of action

Endonuclease inhibition

properties
Molar mass 571.55 g · mol -1
Physical state

firmly

solubility

soluble in DMSO

safety instructions
GHS hazard labeling
no classification available
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Baloxavirmarboxil is a virostatically active drug that is effective against both type A and type B flu virus . The effect is based on the mechanism of inhibition of an early step in the replication cycle of the virus, which was used therapeutically for the first time, by inhibiting the CAP -dependent endonuclease PA .

Baloxavirmarboxil was approved for the treatment of seasonal influenza in February 2018 in Japan and in October 2018 in the United States under the trade name Xofluza . The product was developed by the Japanese company Shionogi Seiyaku , from 2016 in cooperation with Roche . In the multicentre three- arm clinical study CAPSTONE-1 with more than 1400 influenza patients aged 12 to 64 years, the therapeutic effectiveness of a single dose of baloxavirmarboxil was compared with a five-day oseltamivir treatment and placebo .

Individual evidence

  1. ↑ MedKoo Biosciences: Baloxavir marboxil , accessed March 1, 2018
  2. ↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
  3. ↑ Baloxavir marboxil: One tablet for seasonal influenza. Xofluza - a new drug against flu DAZ online , February 28, 2018.
  4. ↑ FDA Approves New Agent Against Flu DAZ Online, February 28, 2018.
  5. ↑ CAPSTONE-1: New antiviral superior to placebo at reducing influenza symptoms . Healio Infectious Disease News, October 17, 2017.